Abstract
Objective: To compare the effect of bedtime and mealtime administration of low dose ursodeoxycholic acid (UDCA) (3-5 mg/kg per day) in gallstone patients on cholesterol saturation index, total mass of biliary lipids within the gallbladder and gallstone dissolution rate. Design: Patients were randomly allocated to either bedtime or mealtime UDCA at a dose similar to that used for gallstone dissolution in combination with chenodeoxycholic acid (CDCA). Methods: In 18 patients with radiolucent gallstones in radiologically functioning gallbladders we measured the total mass of biliary lipids within the gallbladder before and after 1 month of UDCA therapy by gallbladder bile sampling and cholescintigraphy; gallstone dissolution rate was measured after 6 and 12 months of therapy. Results: The dissolution rate was faster for the bedtime regimen (n = 9) than for the mealtime regimen (n = 9), both at 6 months (medians: 40 versus 0%, P <0.05) and at 12 months (70 versus 0%, P <0.05). In the whole group (n = 12), the saturation index was significantly reduced during therapy: this was caused by significantly reduced cholesterol mass within the gallbladder, without changes in the bile acid or phospholipid masses. There was no difference between the two dose timings for saturation index or for the lipid masses within the gallbladder. Conclusions: Using a low dose of UDCA, bedtime administration is more efficacious than mealtime administration for cholesterol gallstone dissolution; the reduction in saturation index is due only to a reduction of cholesterol mass within the gallbladder. These findings suggest that combination therapy involving low doses of both UDCA and CDCA should also be given at bedtime.
| Original language | English |
|---|---|
| Pages (from-to) | 301-306 |
| Number of pages | 6 |
| Journal | European Journal of Gastroenterology and Hepatology |
| Volume | 4 |
| Issue number | 4 |
| Publication status | Published - 1992 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
Cite this
Low dose ursodeoxycholic acid at bedtime and at mealtimes : Effect on mass of lipids within the gallbladder and on gallstone dissolution rate. / Galatola, G.; Jazrawi, R. P.; Northfield, T. C.
In: European Journal of Gastroenterology and Hepatology, Vol. 4, No. 4, 1992, p. 301-306.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low dose ursodeoxycholic acid at bedtime and at mealtimes
T2 - Effect on mass of lipids within the gallbladder and on gallstone dissolution rate
AU - Galatola, G.
AU - Jazrawi, R. P.
AU - Northfield, T. C.
PY - 1992
Y1 - 1992
N2 - Objective: To compare the effect of bedtime and mealtime administration of low dose ursodeoxycholic acid (UDCA) (3-5 mg/kg per day) in gallstone patients on cholesterol saturation index, total mass of biliary lipids within the gallbladder and gallstone dissolution rate. Design: Patients were randomly allocated to either bedtime or mealtime UDCA at a dose similar to that used for gallstone dissolution in combination with chenodeoxycholic acid (CDCA). Methods: In 18 patients with radiolucent gallstones in radiologically functioning gallbladders we measured the total mass of biliary lipids within the gallbladder before and after 1 month of UDCA therapy by gallbladder bile sampling and cholescintigraphy; gallstone dissolution rate was measured after 6 and 12 months of therapy. Results: The dissolution rate was faster for the bedtime regimen (n = 9) than for the mealtime regimen (n = 9), both at 6 months (medians: 40 versus 0%, P <0.05) and at 12 months (70 versus 0%, P <0.05). In the whole group (n = 12), the saturation index was significantly reduced during therapy: this was caused by significantly reduced cholesterol mass within the gallbladder, without changes in the bile acid or phospholipid masses. There was no difference between the two dose timings for saturation index or for the lipid masses within the gallbladder. Conclusions: Using a low dose of UDCA, bedtime administration is more efficacious than mealtime administration for cholesterol gallstone dissolution; the reduction in saturation index is due only to a reduction of cholesterol mass within the gallbladder. These findings suggest that combination therapy involving low doses of both UDCA and CDCA should also be given at bedtime.
AB - Objective: To compare the effect of bedtime and mealtime administration of low dose ursodeoxycholic acid (UDCA) (3-5 mg/kg per day) in gallstone patients on cholesterol saturation index, total mass of biliary lipids within the gallbladder and gallstone dissolution rate. Design: Patients were randomly allocated to either bedtime or mealtime UDCA at a dose similar to that used for gallstone dissolution in combination with chenodeoxycholic acid (CDCA). Methods: In 18 patients with radiolucent gallstones in radiologically functioning gallbladders we measured the total mass of biliary lipids within the gallbladder before and after 1 month of UDCA therapy by gallbladder bile sampling and cholescintigraphy; gallstone dissolution rate was measured after 6 and 12 months of therapy. Results: The dissolution rate was faster for the bedtime regimen (n = 9) than for the mealtime regimen (n = 9), both at 6 months (medians: 40 versus 0%, P <0.05) and at 12 months (70 versus 0%, P <0.05). In the whole group (n = 12), the saturation index was significantly reduced during therapy: this was caused by significantly reduced cholesterol mass within the gallbladder, without changes in the bile acid or phospholipid masses. There was no difference between the two dose timings for saturation index or for the lipid masses within the gallbladder. Conclusions: Using a low dose of UDCA, bedtime administration is more efficacious than mealtime administration for cholesterol gallstone dissolution; the reduction in saturation index is due only to a reduction of cholesterol mass within the gallbladder. These findings suggest that combination therapy involving low doses of both UDCA and CDCA should also be given at bedtime.
UR - http://www.scopus.com/inward/record.url?scp=0026516161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026516161&partnerID=8YFLogxK
M3 - Article
VL - 4
SP - 301
EP - 306
JO - European Journal of Gastroenterology and Hepatology
JF - European Journal of Gastroenterology and Hepatology
SN - 0954-691X
IS - 4
ER -